ArticleJournal of diabetes research2026
Analysis of Biomarkers in Diabetic Foot Ulcer Patients With Dampness-Heat Syndrome Based on 4D-DIA Proteomics Technology.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analysis of Biomarkers in Diabetic Foot Ulcer Patients With Dampness-Heat Syndrome Based on 4D-DIA Proteomics Technology.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDiabetic foot ulcer (DFU), a severe complication of diabetes, impose substantial global health burdens. Dampness-heat syndrome (DHS), a common syndrome in traditional Chinese medicine (TCM), is highly prevalent among DFU patients and closely correlated with treatment response and prognosis. However, the molecular biomarkers associated with DFU in patients with DHS remain poorly understood.
methodsSerum 4D-data-independent acquisition (DIA) proteomics was performed on 16 DFU-DHS patients and six healthy controls (HCs). Differentially expressed proteins (DEPs) were screened by |fold change (FC)| > 1.2 and p < 0.05. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) analyses were conducted. Key biomarkers were validated via enzyme-linked immunosorbent assay (ELISA) in 28 independent DFU-DHS cases.
resultsA total of 201 DEPs were identified between DFU-DHS patients and HCs. Bioinformatics revealed DEPs enriched in lipid metabolism (high-density lipoprotein [HDL] remodeling and cholesterol metabolism) and complement-coagulation cascades. PPI network analysis revealed a core functional module centered on four proteins, APOA1, LCAT, PLTP, and CETP. ELISA validation confirmed the significant dysregulation of these four apolipoproteins in the independent DFU-DHS cohort (all p < 0.05 vs. HCs). The combination of the biomarkers APOA1, LCAT, PLTP, and CETP exhibited a high diagnostic efficacy for DFU-DHS, with an area under the curve (AUC) of 0.9672 based on receiver operating characteristic (ROC) analysis.
conclusionTo our knowledge, this is the first study to employ 4D-DIA proteomics on DFU-DHS. We identified four serum biomarkers (APOA1, LCAT, PLTP, and CETP) linked to dysregulated cholesterol metabolism in DFU-DHS patients, which show diagnostic potential and provide insights for integrating TCM syndrome differentiation with precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.